Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: Analysis from the INFUSE-AMI trial

European Heart Journal: Acute Cardiovascular Care

Volumn 3, Issue 1, 2014, Pages 78-83

  Dizon, José M ^a,b   Brener, Sorin J ^b,c   Maehara, Akiko ^b   Witzenbichler, Bernard ^d   Biviano, Angelo ^a,b   Godlewski, Jacek ^e   Parise, Helen ^b   Dambrink, Jan Henk ^f   Mehran, Roxana ^g   Gibson, C Michael ^h   Stone, Gregg W ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c NEW YORK METHODIST HOSPITAL   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f ISALA HOSPITAL   (Netherlands)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiac magnetic resonance imaging; electrocardiogram; ST elevation myocardial infarction; ST segment resolution

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANGIOCARDIOGRAPHY; ANTAGONISTS AND INHIBITORS; ANTERIOR WALL MYOCARDIAL INFARCTION; CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTERIOR WALL MYOCARDIAL INFARCTION; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 84925224412     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872613508658     Document Type: Article

References (23)

1. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index:prospective cohort study. Heart 2008; 94: 730–736.
2. Hallen J, Buser P, Schwitter J, et al. Relation of cardiac troponin I measurement at 24 and 48 hours to magnetic resonance-determined infarct size in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 1472–1477.
3. Klug G, Mayr A, Mair J, et al. Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI. Clin Res Cardiol 2011; 100: 501–510.
4. Turer AT, Mahaffey KW, Gallup D, et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med 2005; 23: 12.
5. Licka M, Zimmermann R, Zehelein J, et al. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002; 87: 520–524.
6. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100: 1992–2002.
7. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST-segment elevation resolution:a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384–391.
8. Schroder R, Wegscheider K, Schroder K, et al. Extent of early ST-segment elevation resolution:a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens:a substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995; 26: 1657–1664.
9. Van't Hof AW, Liem A, de Boer MJ, et al. Myocardial Infarction Study Group. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 1997; 350: 615–619.
10. Matetzky S, Novikov M, Gruberg L, et al. The significance of persistent ST elevation versus early resolution of ST-segment elevation after primary PTCA. J Am Coll Cardiol 1999; 34: 1932–1938.
11. Claeys MJ, Bosmans J, Veenstra L, et al. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction:importance of microvascular reperfusion injury on clinical outcome. Circulation 1999; 99: 1972–1977.
12. Prasad A, Stone GW, Aymong E, et al. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. Am Heart J 2004; 147: 669–675.
13. McLaughlin MG, Stone GW, Aymong E, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol 2004; 44: 1215–1223.
14. Buller CE, Fu Y, Mahaffey KW, et al. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Insights from the Assessment of Pexelizumab in acute myocardial infarction (APEX-AMI) trial. Circulation 2008; 118: 1335–1346.
15. Tibrewala AV, Asch F, Shah S, et al. Association of size of myocardial scar and persistence of ST-segment elevation after healing of anterior wall myocardial infarction. Am J Cardiol 2007; 99: 1106–1108.
16. Weaver JC, Ramsay DD, Rees D, et al. Dynamic changes in ST-segment resolution after myocardial infarction and the association with microvascular injury on cardiac magnetic resonance imaging. Heart Lung Circ 2011; 20: 111–118.
17. Engblom H, Strauss DG, Heden B, et al. The evaluation of an electrocardiographic myocardial ischemia acuteness score to predict the amount of myocardial salvage achieved by early percutaneous coronary intervention. Clinical validation with myocardial perfusion single photon emission computed tomography and cardiac magnetic resonance. J Electrocardiol 2011; 44: 525–532.
18. Gibson CM, Maehara A, Lansky AJ, et al. Rationale and design of the INFUSE-AMI study: a 2 X 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J 2011; 161: 478–486.
19. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction. The INFUSE-AMI randomized trial. JAMA 2012; 307: 1817–1826.
20. Thygesen K, Alpert JS, Jaffe AS, et al.; the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 2012; 60: 1581–1598.
21. Bang LE, Ripa RS, Grande P, et al. Comparison of infarct size changes with delayed contrast-enhanced magnetic resonance imaging and electrocardiogram QRS scoring during the 6 months after acutely reperfused myocardial infarction. J Electrocardiol 2008; 41: 609–613.
22. De Luca G, Suryapranata H, Ottervanger JP, et al. Postprocedure single-lead ST-segment deviation and long-term mortality in patients with ST-segment elevation myocardial infarction by primary angioplasty. Heart 2008; 94: 44–47.
23. Brener SJ, Maehara A, Dizon JM, et al. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients with Large Anterior Myocardial Infarction) Trial. JACC Cardiovasc Interv 2013; 6: 718–724.